Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from SNY

Sanofi's Rilzabrutinib Data In Autoimmune Blood Disorder Published In New England Journal of Medicine

Results from the Phase 1/2 dose-finding study evaluating Sanofi SA's (NASDAQ:SNY) rilzabrutinib in adults with heavily pre-treated immune thrombocytopenia (ITP) were published in the New England Journal of Medicine. Results demonstrate that rilzabrutinib treatment led to a rapid and durable increase in platelet count and supports an acceptable safety profile. Sanofi is investigating…

Sanofi To List Drug Ingredient Spin-Off EUROAPI On Euronext Paris in May

Sanofi To List Drug Ingredient Spin-Off EUROAPI On Euronext Paris in May

Sanofi SA (NASDAQ: SNY) plans to list its drug ingredients subsidiary EUROAPI on May 6, saying the business is set to grow and improve its profitability as a separate business.

EMA Starts Review Of Sanofi-GlaxoSmithKline's COVID-19 Vaccine

EMA Starts Review Of Sanofi-GlaxoSmithKline's COVID-19 Vaccine

The European Medicines Agency has started reviewing Sanofi SA (NASDAQ:SNY) and its partner GlaxoSmithKline Plc's (NYSE:GSK) application seeking conditional authorization for their COVID-19 vaccine. The vaccine candidate, Vidprevtyn, was already being evaluated under a rolling review by EMA. The drugmakers had earlier said that they would seek regulatory approval for their COVID-19 vaccine to be…

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

IGM Biosciences Shares Surge After Oncology/Immunology Pact With Sanofi

Sanofi SA (NASDAQ: SNY) and IGM Biosciences Inc (NASDAQ: IGMS) have signed an exclusive worldwide collaboration agreement for IgM antibodies agonists against

Dividend Investors: 5 Stocks to Shore Up Your Portfolio

Amid the current market fluctuations owing to continuing geopolitical tensions, soaring oil prices, a rising interest rate environment, and supply chain disruptions, it could be wise to add quality dividend stocks Medtronic (MDT), Sanofi (SNY), Nippon Telegraph, and Telephone (NTTYY), Honda Motor (HMC) and Hewlett Packard (HPE) to one’s portfolio…

Sanofi, Seagen Collaborate For Antibody-Drug Conjugates Against Cancer Targets

Sanofi SA (NASDAQ:SNY) and Seagen Inc (NASDAQ:SGEN) have announced an exclusive collaboration agreement to design, develop, and commercialize antibody-drug conjugates (ADCs) for up to three cancer targets. The collaboration will utilize Sanofi's proprietary monoclonal antibody (mAb) technology and Seagen's proprietary ADC technology. ADCs are antibodies engineered to deliver potent anti-cancer drugs to tumor cells expressing…

Why Sanofi Shares Are Trading Lower Today

Sanofi SA (NASDAQ: SNY) stock slid after its drug candidate, amcenestrant, to fight a common type of breast cancer,

inkl

Read news from The Economist, FT, and more,
with one subscription

Sanofi-SOBI Hemophilia Candidate Aces Late-Stage Study In Pretreated Patients

Sanofi-SOBI Hemophilia Candidate Aces Late-Stage Study In Pretreated Patients

Swedish Orphan Biovitrum AB (OTC: BIOVF) and Sanofi SA (NASDAQ: SNY) have announced topline results from the XTEND-1 phase 3 study of efanesoctocog alfa (BIVV001) in previously treated severe hemophilia A pa

AstraZeneca-Sanofi's Nirsevimab Shows 75% Efficacy Against RSV In Healthy Infants

AstraZeneca-Sanofi's Nirsevimab Shows 75% Efficacy Against RSV In Healthy Infants

AstraZeneca Plc (NASDAQ:AZN) and Sanofi SA (NASDAQ:SNY) have shared detailed results from the MELODY Phase 3 trial evaluating nirsevimab in respiratory syncytial virus (RSV). The data showed that a single dose of nirsevimab met the primary efficacy endpoint reducing the incidence of medically attended lower respiratory tract infections caused by RSV by 74.5% compared to…

Sanofi Taps Adagene's 'Masking' Tech In Over $2.5B Immuno-Oncology Pact

Sanofi Taps Adagene's 'Masking' Tech In Over $2.5B Immuno-Oncology Pact

Sanofi SA (NASDAQ:SNY) has signed a collaboration with Adagene Inc (NASDAQ:ADAG) to advance two preclinical immuno-oncology candidates and an option to develop two more. Sanofi is paying $17.5 million upfront and promising up to $2.5 billion in potential milestones. Under the terms of the agreement, Adagene will be responsible for early-stage research activities to develop…

3 Unstoppable Healthcare Stocks to Buy and Hold in 2022

3 Unstoppable Healthcare Stocks to Buy and Hold in 2022

The healthcare industry has ridden a promising wave of innovation and investments over the past few years. Also, with continuing acceleration in the digital transformation of healthcare and breakthrough developments, with healthcare expenditure expected to grow in the coming years, the industry’s prospects look bright. Therefore, we think healthcare stocks…

Sanofi-GSK Prepare Regulatory Filings For COVID-19 Vaccine After Booster Data

Sanofi-GSK Prepare Regulatory Filings For COVID-19 Vaccine After Booster Data

Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline plc (NYSE: GSK) are

5 Best Healthcare Stocks to Buy as a Hedge Against Inflation

5 Best Healthcare Stocks to Buy as a Hedge Against Inflation

The healthcare sector has historically provided a better hedge against inflation than gold because of the inelastic demand for its products and services. Rising healthcare needs of an aging population, integration of advanced technologies, and breakthroughs in clinical trials brighten the sector’s prospects. Therefore, fundamentally-sound and undervalued healthcare stocks Sanofi…

Sanofi-Regeneron's Dupixent Falls Short In Chronic Spontaneous Urticaria Trial

Sanofi-Regeneron's Dupixent Falls Short In Chronic Spontaneous Urticaria Trial

Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have

Get all your
news in one place.

100’s of premium titles.
One news app.

Hopeful Golden Cross Forms On Sanofi's Chart

If history is any guide, there may be good fortune ahead for shares of Sanofi (NASDAQ:SNY). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock.

USA Today Sports Media Group

Pistons interested in Mitchell Robinson

One note worth keeping in mind with Robinson: The Detroit Pistons are among the teams who've had a degree of interest in the 23-year-old, per SNY sources. Robinson would fit the team's desire to find players on the same timeline as rookie Cade ...

Sanofi Records Q4 Topline, Bottomline Growth As Blockbuster Eczema Drug Soars

Sanofi SA's (NASDAQ: SNY)

What Does Sanofi's Debt Look Like?

Over the past three months, shares of Sanofi (NASDAQ:SNY) increased by 1.88%. Before we understand the importance of debt, let us look at how much debt Sanofi has.

Get all your
news in one place.

100’s of premium titles.
One news app.

Regeneron, Sanofi Withdraw FDA Application For Libtayo's Expanded Use

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and its partner Sanofi SA (NASDAQ: SNY) have

Second Dupixent Phase 3 Trial Confirms Significant Improvements In Inflammatory Skin Disease

Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have

People

Mitchell Robinson

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

World Health Organization

Detroit Pistons

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

347,581 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play